Surgical Laser Technologies clarifies claim:
This article was originally published in Clinica
Executive Summary
With reference to an article in Clinica No 870, p 9, entitled "CorMedica abandons laser heart revascularisation energy source in search for better, cheaper option", Surgical Laser Technologies, which is suing CorMedica for $266,000 it claims represents unpaid bills, clarifies that it was informed by CorMedica that it did not currently have the means to pay the amount owed, but that it was diligently seeking such means. Based on this, Surgical Laser Technologies says it expects and believes that when and if CorMedica is successful in raising additional financing, CorMedica will settle the amount in full.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.